Rixa Health review

Rixa Health discloses two things most telehealth sellers withhold. Its clinicians are named with their credentials — Timothy Scott DO, Shawn Stansbery DO, Daniel Neumeyer DO and Mia Scott FNP-BC, each described as a certified peptide specialist — and its three partner pharmacies are published with street addresses and phone numbers. But a reader can see almost nothing of its peptide offer. There is no dedicated peptide page; peptides appear only as a bookable area of care and an "other peptides" line on the weight-loss page, and the FAQ says their prices can be discussed as needed. No peptide is named in the site's visible copy; PT-141 appears only in the description of its men's sexual-health service. That is a real practice with a peptide catalog you have to ask for.

Rixa Health is a direct-to-consumer functional-medicine telehealth practice whose listed services are medical weight loss (including semaglutide and tirzepatide oral dissolving tablets), perimenopause and menopause care, GLP-1s for teens, testosterone restoration, thyroid health and custom functional lab work, with men's sexual health and peptides available by booking. It also runs a supplement shop. Care is described as root-cause and preventive, with required monthly follow-ups during the first six months of a weight-loss program, and it operates cash-pay with HSA and FSA cards accepted.

Booked consultations with named clinicians rather than an anonymous asynchronous queue, which is the practice's real differentiator. Four providers are named with their degrees, training and years in practice, and all four are described as certified peptide specialists — the DOs as board-certified physicians and Mia Scott as an ANCC board-certified nurse practitioner. Its partner-pharmacies page names Belmar Pharma Solutions in Youngtown, Arizona; Red Rock Pharmacy in Springville, Utah; and Seven Cells Pharmacy in Stuart, Florida, each with a street address and phone number. Naming both the clinicians and the pharmacies is more accountability than most telehealth sellers offer. Two things temper it. The catalog is opaque: there is no dedicated peptide page, "Peptide" appears only as an area of care on the booking page and an "other peptides" entry on the weight-loss page, and no peptide is named in the visible copy, so you discover what is on offer at consult. And coverage is narrower than a nationwide service: the booking page lists 45 states plus DC, and says that if your state is missing there is no licensed provider there yet; Alaska, Arkansas, Hawaii, North Dakota and South Dakota are absent. Weight-loss patients are required to attend monthly follow-ups for the first six months, which is a genuine adherence-and-safety structure rather than a billing device. The intake is screened before the visit, and the FAQ says you are not charged if something disqualifies you. A $25 first-visit discount is advertised and excludes asynchronous visits, including the men's vitality flow.

Half published, and the unpublished half is the half that matters here. GLP-1 pricing is published in detail — injectable semaglutide in five levels from $195 to $310 and tirzepatide in six levels from $280 to $525, each stated per four-week or five-week block covering the visit and the pass-through cost of medication shipped by the compounding pharmacy, plus oral dissolving tablets from $140 for 30 days. Those are weight-loss figures, the injectables are billed by cycle rather than by calendar month, and none of them is a peptide price. Peptide therapy is the part that genuinely is not published: the FAQ says costs vary with the medication or peptide you are interested in and that prices for its other peptides can be discussed as needed, and the pricing page lists none. So there is no peptide figure to quote. Before booking, ask which specific peptide is being proposed, at what dose and concentration, what a month costs, which of the three named pharmacies will prepare it, and whether the price includes the follow-up visits. Cash-pay only, with HSA and FSA cards accepted.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Rixa names its three partner compounding pharmacies, which is the disclosure that actually lets a patient check licensure, but compounded sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, there is exactly one molecule here we can assess, because it is the only one Rixa attaches to a service. PT-141, or bremelanotide, is a melanocortin-receptor agonist and an unusual case: the injectable (Vyleesi) is an FDA-approved drug, but for one narrow indication only — acquired, generalized hypoactive sexual desire disorder in premenopausal women. Prescribed to a man for erectile or libido complaints, as the men's sexual-health description implies, it is off-label use of an approved molecule, and a compounded version is not the approved product. Its known effects include nausea, flushing and transient blood-pressure rises, which is why the approved label restricts dosing frequency. Everything else in its peptide offer is unassessable by design: a service without a named molecule cannot be checked against evidence, and a reader cannot be sent to a monograph for a compound nobody has named. The sexual-health line also carries sildenafil and tadalafil, which are conventional approved PDE5 inhibitors and a different matter entirely. Individual results vary.